Shalabh Gupta, MD, MPA
Founder, President & CEO
Shalabh Gupta, MD, MPA is the founder and CEO of Globavir, Inc. In early 2011, Dr. Gupta founded BioCycive Inc., a biotechnology company focused on oncology. BioCycive’s lead program, BC 001, was partnered with Sorrento Therapeutics and then with Nantworks LLC in 2015. BioCycive later became Globavir’s wholly owned subsidiary.
Globavir was formed with several technologies licensed from Stanford University, where Dr. Gupta serves an advisor to the SPARK program at the Stanford School of Medicine. SPARK is designed to identify partnerships between academia and enterprise to allow academic discoveries to move from Stanford's laboratories to commercial application.
Prior to founding BioCycive and Globavir, Dr. Gupta worked at Genentech in commercial strategy for immunology. His work was focused on Genentech's immunology products with regard to competitive positioning and working with brand teams to create franchise strategies.
Before Genentech, Dr. Gupta had a career on Wall Street. Dr. Gupta worked as a stock analyst at UBS covering large cap pharmaceuticals, and while at Rodman & Renshaw, he covered small/mid cap biotechnology companies. Besides launching new stock coverage, his work included analysis of M&A targets and strategic partnerships. Dr. Gupta has served as an advisor to an early stage venture fund based in New York, where he managed the life sciences portfolio. While there, he oversaw the due diligence process for all venture deals presented for fund investment, in both the private and public markets.
Earlier in his career, Dr. Gupta was a board certified physician, and served as medical director for several early stage medical device and biotechnology companies, and is experienced in running FDA clinical trials. Dr. Gupta also maintained a faculty appointment at the NYU School of Medicine while an active clinician there for over a decade.
Gilad Gordon, MD, MBA
Dr. Gilad S. Gordon is the Chief Medical Officer of Globavir. Dr. Gordon has nearly 30 years of experience designing and implementing clinical trials leading to the approval of new drug and vaccine candidates. He has focused on the clinical development of new therapies, devices and diagnostics for the treatment of disease (including cancer, hepatitis, infectious diseases, mental disorders, and diabetes) and has worked as both a consultant and as a senior executive at a number of biotechnology companies.
From 2011 until its acquisition by Takeda in 2013, Dr. Gordon worked as the Chief Medical Officer for Inviragen, Inc. which was developing vaccines for Dengue fever and for Hand, Foot and Mouth disease.
In addition, Dr. Gordon has extensive expertise in health economics, health policy, and medical information systems. Additionally, Dr. Gordon serves as a Board Member for both the Ruesch Center of the Georgetown Lombardi Cancer Center and Caring for Colorado Foundation.
Dr. Gordon received an AB in Biochemistry from Harvard College in 1979, an MD from the HST program at Harvard Medical School and MIT in 1983, and an MBA from the University of Washington in 1988. He completed an internship and residency in Internal Medicine at the University of Colorado Health Sciences Center in 1986 and was a Senior Fellow in the Robert Wood Johnson Clinical Scholars Program at the University of Washington from 1986 to 1988. He is Board Certified in Internal Medicine and is currently also a Clinical Associate Professor of Medicine at the University of Colorado.
Laurence Nore, MBA
VP, Corporate Development
Mrs. Laurence Nore, MBA, is the Vice President of Corporate Development for Globavir. Mrs. Nore has over 20 years of experience in corporate & business development, strategic marketing and finance, with 15 years spent in the biotechnology industry including diagnostics.
Most recently Laurence was the Lead of Biomarkers & Companion Diagnostics at EMD Millipore (Merck group) where she was responsible for building the CDx business as well as managing the biomarker testing service franchise.
Prior to EMD, she was Director of Business Development at Ventana Medical Systems/Roche Diagnostics, where she led the acquisition of BioImagene. Prior to Ventana she was responsible for the launch of a Breast Cancer genetic test developed at Perlegen, a private molecular diagnostic company, and developed the investment rationale for their Series E round. Mrs. Nore also brings several years of experience in Therapeutics at Amgen and PDL BioPharma where she was responsible for Licensing, M&A, Alliance management and post-merger integration. She holds an MBA from the Anderson School at UCLA.